PI-273 |
Katalog-Nr.GC39155 |
PI-273 ist ein erster reversibel und spezifischer Phosphatidylinositol-4-Kinase (PI4KIIα)-Inhibitor mit einer IC50 von 0,47 μM. PI-273 kann die Proliferation von Brustkrebszellen hemmen, den Zellzyklus blockieren und Zellapoptose induzieren.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 925069-34-7
Sample solution is provided at 25 µL, 10mM.
PI-273 is a first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM. PI-273 can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis[1].
[1]. Li J, et al. PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KIIα, Inhibits the Growth of Breast Cancer Cells. Cancer Res. 2017 Nov 15;77(22):6253-6266.
Average Rating: 5
(Based on Reviews and 2 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *